Never miss a great news story!
Get instant notifications from Economic Times
AllowNot now


You can switch off notifications anytime using browser settings.

Portfolio

Loading...
Select Portfolio and Asset Combination for Display on Market Band
Select Portfolio
Select Asset Class
Show More
Download ET MARKETS APP

Get ET Markets in your own language

DOWNLOAD THE APP NOW

+91

CHOOSE LANGUAGE

ENG

  • ENG - English
  • HIN - हिन्दी
  • GUJ - ગુજરાતી
  • MAR - मराठी
  • BEN - বাংলা
  • KAN - ಕನ್ನಡ
  • ORI - ଓଡିଆ
  • TEL - తెలుగు
  • TAM - தமிழ்
Drag according to your convenience
ET NOW RADIO
ET NOW
TIMES NOW

China to speed up drug approvals, will accept overseas trial data

REUTERS|
Updated: Oct 09, 2017, 10.25 AM IST
0Comments
Generally, draft proposals announced in China are later implemented much as they first appear.
Generally, draft proposals announced in China are later implemented much as they first appear.

SHANGHAI: China is looking to speed up approvals for new drugs and plans to accept data from clinical trials carried out overseas, a potential boon for international drugmakers and patients who often face lengthy delays for new medicines to reach the market.

The move, announced by the Cabinet late on Sunday, said foreign drug trial data would be accepted in a bid to accelerate approvals and help China close an innovation gap with developed international markets.

"Clinical trial data from overseas centres that complies with Chinese drug and medical device registration requirements can be used to make registration applications in China," the draft proposals posted on the State Council's website said.

Generally, draft proposals announced in China are later implemented much as they first appear.

The move should help speed up approvals in the world's second largest drug market, after the United States, where global firms have faced rising challenges from Chinese rivals and authorities are keen to squeeze down prices.

The proposal said that firms looking to register drugs or medical devices for the first time would need to provide clinical trial data related to any racial divergence relevant to the Chinese market.

The announcement comes as China aims to boost its drug industry and support a shift from generic drugs and towards more innovative medicines and medical equipment - a trend that raises a longer-term challenge to global firms.

The State Council added that the changes would make China's industry more competitive and help meet the clinical needs of its nearly 1.4 billion people, for whom high costs and access to healthcare are significant issues.

"Overall, China's support for scientific innovation with drugs and medical devices is lacking, and the quality of products on the market still falls short of top international levels," the central government body said.

"We must speed up the examination and approval of urgently needed drugs and medical devices," it added.

0Comments

Also Read

China jabs back at Donald Trump's barb over South China Sea

China stocks fall the most in 2 weeks, China Unicom tumbles

Philippines says China has agreed no new expansion in South China Sea

China says US destroyer in South China Sea violated its security

China relaxes yuan hedging rules

Comments
Add Your Comments

Loading
Please wait...